Pre-Market: ALSEN.PA Sensorion SA down 34.08% on 24 Mar 2026: catalyst check

ALSEN.PA stock plunged 34.08% to €0.41 in pre-market trading on 24 Mar 2026, making Sensorion SA one of the top losers on EURONEXT. The move came on 10,851,073.00 shares, well above the 3,0​*294,657.00 average volume. Sensorion (ALSEN.PA) is a clinical-stage biotechnology company focused on inner ear therapies; the drop follows the company’s six-month follow-up release on its gene therapy program. We summarise drivers, key ratios, technicals and a model-based forecast to help frame the pre-market sell-off for European investors.

Price action and immediate drivers for ALSEN.PA stock

The stock fell from a previous close of €0.62 to €0.41 in pre-market on heavy volume (10,851,073.00). That decline equals -34.08% for the session and pushed price below the 50-day average of €0.38 and above the year low of €0.15. Market reaction appears disconnected from the clinical update headline; the high volume suggests aggressive selling and position rebalancing ahead of normal trading. For context, ALSEN.PA opened the day at €0.57 and recorded an intraday high of €0.60 before the drop.

Fundamentals, valuation and ALSEN.PA stock metrics

Sensorion (ALSEN.PA) shows biotech characteristics: negative earnings, meaningful R&D spend and a tight cash buffer per share. Key figures: EPS -0.09, PE -4.56, PB 2.77, market cap €123,138,105.00, and shares outstanding 300,336,842.00. Current ratio stands at 4.59, giving short-term liquidity cover. Revenue per share is €0.01 and operating cash flow per share is -€0.09, reflecting development-stage cash burn. These metrics explain why equity is sensitive to news and volume shocks in the EURONEXT market.

Meyka AI rating and ALSEN.PA stock outlook

Meyka AI rates ALSEN.PA with a score out of 100: 66.79/100 — Grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade balances a strong current ratio and cash per share against negative profitability and high price-to-sales. Investors should treat this as one input, not investment advice.

Technical setup and trading signals for ALSEN.PA stock

Technical indicators show mixed momentum. RSI is 44.41, MACD near neutral and ADX 46.75, indicating a strong short-term trend. Bollinger Bands sit at upper €0.74 / middle €0.49 / lower €0.23; price trading near the lower band increases short-term volatility risk. Average volume is 2,994,657.00, while today’s volume is 10,851,073.00, a relVolume of 3.62. Support sits near the year low €0.15 and resistance at the year high €0.81.

Clinical news, catalysts and market context for ALSEN.PA stock

Sensorion released six-month follow-up data for its Audiogene Phase 1/2 SENS-501 program, a positive development for gene therapy in inner ear disorders. Despite that, shares fell sharply, suggesting the market weighed other factors such as profit-taking or position adjustments. Read the clinical summary at Investing.com: Sensorion reports sustained efficacy in gene therapy hearing trial and a regional report here: Sensorion reporta eficacia sostenida en ensayo de terapia génica. These releases remain potential catalysts for re-rating if future cohorts confirm benefit.

Risks, liquidity and realistic price targets for ALSEN.PA stock

Primary risks include continued negative earnings, high volatility, and dilution risk typical for clinical-stage biotechs. Liquidity is adequate intraday — average daily volume 2,994,657.00 — but the high float and retail interest can drive large swings. Practical price targets: Bear €0.15 (year low), Base €0.27 (monthly model level), Bull €0.80 (year high). These targets are scenario guides, not guarantees, and should be used with risk controls and position sizing.

Final Thoughts

ALSEN.PA stock is a top pre-market loser on EURONEXT after a -34.08% move to €0.41 on 24 Mar 2026. The sell-off came despite clinical follow-up data for SENS-501, highlighting how development-stage biotech shares trade more on liquidity flows than headlines. Key fundamentals show EPS -0.09, PE -4.56, PB 2.77, and a market cap of €123,138,105.00; the firm has a healthy current ratio (4.59) but negative operating cash flow per share (-€0.09). Meyka AI’s model projects a yearly price of €0.14, implying about -64.76% versus today’s €0.41; monthly and quarterly projections are €0.27 (-34.15%) and €0.10 (-75.61%) respectively. Meyka AI provides these model-based projections as one scenario; forecasts are not guarantees. For traders: watch volume and whether price holds above €0.23 (Bollinger lower band) or re-tests the year low €0.15. For longer-term investors, follow upcoming clinical readouts and capital markets activity closely. For the latest trade data see the Sensorion page on Meyka: Sensorion ALSEN.PA on Meyka.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.